Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.
| Revenue (TTM) | $8.26B |
| Gross Profit (TTM) | $4.43B |
| EBITDA | $1.12B |
| Operating Margin | 5.58% |
| Return on Equity | 34.80% |
| Return on Assets | 2.75% |
| Revenue/Share (TTM) | $47.42 |
| Book Value | $28.64 |
| Price-to-Book | 2.80 |
| Price-to-Sales (TTM) | 1.81 |
| EV/Revenue | 2.259 |
| EV/EBITDA | 7.49 |
| Quarterly Earnings Growth (YoY) | -91.00% |
| Quarterly Revenue Growth (YoY) | -3.00% |
| Shares Outstanding | $173.18M |
| Float | $147.06M |
| % Insiders | 15.07% |
| % Institutions | 76.36% |
Volatility is currently expanding
Nelson Peltz's Trian Fund Management has emerged as the largest institutional shareholder of Solventum (NYSE:SOLV | SOLV Price Prediction), holding 7.09 million shares, or roughly 4.75% of outstanding stock.
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
SOLV's innovation, cost savings and strong segment demand support growth, while raw material cost increases remain a key risk.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
EAGAN, Minn., July 15, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its second quarter fiscal 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.
Solventum Corporation continues to trade at a noticeable discount, with shares showing resilience versus med-tech peers despite tepid growth expectations. Management targets 3–4% underlying revenue growth for 2026, with SOLV EPS likely at the high end of the $6.40–$6.60 range. Restructuring and portfolio optimization offer significant upside, as SOLV's business units lack natural synergies and could be divested.
The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
SOLV heads into 2026 balancing AI coding growth, cost savings, tariff pressure and a potential 2027 margin risk tied to its 3M supply deal.
Solventum Corporation (SOLV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SOLV and any ticker you trade — then tracks every position and per-strategy win rate.
